This study has been performed to test the hypothesis that different oestrogen receptor beta (ER ) splice variants may be important determinants of clinical parameters, including outcome, in post-menopausal women with breast cancer receiving adjuvant endocrine treatment but no chemotherapy. Splice variants ER 1, ER 2 and ER 5 have been analysed by semi-quantitative RT-PCR in a cohort of 105 patients with primary breast cancer. Clinical correlates included age, grade, size, nodal status, ER , progesterone receptor, Ki67, relapse-free survival (RFS) and overall survival (OS). Seventy per cent of cases were ER 1 positive, 69% ER 2 positive and 70% ER 5 positive. Within the cohort, 47% were positive for all three variants while 10% were negative for all three. ER 1 exhibited no discernible relationship with disease outcome. ER 2 and ER 5 expression was significantly associated with better RFS (P,0·005), and ER 2 with better OS (P=0·0002). In multivariate analysis, ER 2 (P=0·006), nodal status and the level of Ki67 expression were independent predictors for RFS while ER 2 (P=0·0008) and Ki67 status were independent predictors for OS. In the ER -positive cases, or in the subset of those receiving adjuvant tamoxifen, ER 2 was significantly associated with good RFS (P,0·0005) and was the only independent marker of OS. We conclude that precise identification of splice variants of ER are more important assessors than is ER 1 alone of the biological status of individual breast cancers, and hence in predicting their response to endocrine therapy.
Introduction
Oestrogen receptor alpha (ER ), as a measure of steroid hormone receptor status, is a currently accepted prognostic marker used to predict the response of an individual breast cancer to hormone therapy (Pertschuk & Axiotis 1999) . However, it is known that up to 40% of breast tumours with positive ER status do not respond to endocrine therapy (Locker 1998) . Reasons for this lack of response are poorly understood. However, the relative expression of ER may be an important modulator of oestrogenic hormone manipulation. A variety of studies have employed RT-PCR or in situ hybridisation to analyse the mammary expression of ER mRNA (Enmark et al. 1997 , Vladusic et al. 1998 , Speirs et al. 1999a , Iwao et al. 2000a ,b, Kurebayashi et al. 2000 , Bieche et al. 2001 , Cullen et al. 2001 , de Cremoux et al. 2002 , Tong et al. 2002 . However, these studies are conflicting, reflecting either differences in case selection or limitations of the detection techniques. Nevertheless, it has been suggested that the level of ER expression has prognostic significance in breast cancer (Speirs et al. 1999a , Jarvinen et al. 2000 , Knowlden et al. 2000 , Speirs & Kerin 2000 , Mann et al. 2001 , Fuqua et al. 2003 . ER has been associated with markers of low biological aggressiveness such as negative axillary nodal status (Jarvinen et al. 2000) , low morphological grade (Jarvinen et al. 2000 , Speirs & Kerin 2000 and improved survival (Mann et al. 2001 , Omoto et al. 2001 . The ratio of ER :ER has been shown to predict progression to neoplasia and malignancy in the breast (Shaaban et al. 2003a ) and the ratio ER :ER mRNA changes during mammary carcinogenesis (Leygue et al. 1998 ) together with relative amounts of different ER variants .
ER 1, considered to be the full-length or wild-type ER , is able to form heterodimers with ER (Cowley et al. 1997) and in this may contribute to differences in ER-dependent gene expression. Some ER variants resulting from differential splicing are expressed in a cell-type and tissue-type specific manner (Saunders 1998) , are expressed as proteins (Saunders et al. 2002) and can interact with both ER 1 and ER (Moore et al. 1998) . Hence these splice variants may be considered as functionally distinct isoforms of ER . For example, ER 2 (also known as ER cx) is a variant that utilises an alternative exon 8 (Moore et al. 1998) , a change that results in relatively poor binding to oestradiol and a dominant negative effect on ER function (Ogawa et al. 1998) . The putative ER 5 protein sequence diverges from ER 1 at the same point as ER 2 (amino acid 469) by alternative splicing (Moore et al. 1998) . As in ER 2 the C-terminal of this ER 5 protein is truncated, resulting in loss of the AF-2 core domain and differences in ligand binding (Peng et al. 2003) . Such effects may modulate the action of therapies directed against ER , such as the endocrine treatments used in breast cancer. Expression of ER variants has been shown to vary between different tumours and cell lines , Iwao et al. 2000a ,b, Omoto et al. 2002 , Tong et al. 2002 . However, expression of individual splice variants is not known with respect to particular clinical parameters, including treatment or outcome, principally because many mRNA studies utilised RT-PCR primers designed against sequences common to all splice variants (Leygue et al. 1998 , Speirs et al. 1999a ,b, Iwao et al. 2000a ,b, Knowlden et al. 2000 , Kurebayashi et al. 2000 , Bieche et al. 2001 , Cullen et al. 2001 , de Cremoux et al. 2002 and variant-specific antibodies have not been widely available. Levels of mRNA for ER 2 and ER 5 are recognised to be higher than those for the ER 1 variant , Iwao et al. 2000a , hence many of the non-specific RT-PCR studies to date may reflect expression of these variants. It is therefore important to determine the individual relationships between ER variants and clinical and pathological factors, so as to understand better their relative contributions to breast disease. To this end, we have analysed a retrospective cohort of primary breast cancers, representing a series of cases receiving endocrine therapy but not chemotherapy. Typically such clinically defined cohorts are heterogeneous, allowing associations with other pathological factors to be considered, but requiring that multivariate statistical analysis be applied when considering outcome data.
The literature contains detailed consensual reference to ER splice variants ER 1, ER 2/ ER cx and ER 5, including the agreed primer sequences for PCR. Although not exhaustive, analysis of these three splice variants is sufficient to identify those splice variants commonly expressed by normal breast and breast carcinomas. Therefore, the purpose of the present study was to test the hypothesis that ER splice variant expression in breast cancer is related to patient outcome data when patients receive only endocrine therapy in the absence of chemotherapy.
Materials and methods

Subjects
Patients undergoing treatment, at the Royal Liverpool University Hospital, for invasive breast cancer during the period 1993-1999 were identified by the Cancer Tissue Bank Research Centre (CTBRC). Tissues were collected by CTBRC with full consent and appropriate ethical committee approval and RNA was prepared by standard methods. Clinical follow-up data were recorded by retrospective case-note review, but were unavailable for some variables in a limited number of cases. All cases were subjected to histopathological review according to the guidelines of the UK NHSBSP (National Coordinating Group for Breast Screening Pathology 1997), by three investigators (P A O'N, C S F and Prof. J P Sloane). Histopathological sections of tissues adjacent to that used for RNA preparation were assessed and cases comprising at least 50% tumour cells were included (90% of such cases contained 75% or more tumour cells). Cases were only included if the quality of the prepared cDNA was considered adequate (see below). Consequent upon these caveats, the study population (Table 1 ) comprised 105 post-menopausal women treated with surgery, either with or without radiation treatment and no chemotherapy. The median age was 68 years (range 48-88). Most cases were invasive ductal carcinomas of no special type. Other invasive carcinoma types included lobular (n=10), mucinous (n=4), medullary (n=1), papillary (n=1), tubular (n=1), metaplastic (n=1) and mixed mucinous/papillary (n=1).
All patients received adjuvant hormone therapy but no chemotherapy. For 89 of the cases, endocrine therapy comprised only adjuvant tamoxifen; adjuvant treatment for seven further patients was received as part of the Arimidexor Tamoxifen Alone or in Combination (ATAC) trial and could not be determined. Only nine patients received primary tamoxifen therapy prior to surgery, six of these patients then received adjuvant tamoxifen and three received adjuvant anastrozole. Hence surgical specimens for all but these nine cases were collected prior to commencement of endocrine therapy. Since routine histopathology did not include steroid receptor analysis until 1996, some cases were subsequently found to be ER negative.
Ethical approval for this study was obtained from all relevant bodies.
Immunostaining
Immunostaining data for ER , progesterone receptor (PgR) and Ki67 were made available by the CTBRC. Briefly, a mouse anti-human ER monoclonal antibody (Clone 1D5; Dako Ltd, Ely, Cambridge, UK) was used for the immunohistochemical detection of ER . PgR status was assessed using a mouse monoclonal anti-PgR antibody (Clone 1A6; Novacastra, Newcastle upon Tyne, UK) and Ki67 status was assessed using polyclonal rabbit anti-human Ki67 antibody (Ki67p; Novacastra). Formalin-fixed and paraffin waxembedded sections were immunostained by methods identical to those previously described (Shaaban et al. , 2003b . To maximise consistency of scoring, only nuclei having moderate or strong staining were regarded as positive, independently of cytoplasmic staining. The percentage of nuclear-stained epithelial cells was calculated as a proportion of the total number of epithelial cells present. A 10% cut-off was the conventional criterion to define ER staining, as previously described and PgR staining. Staining for Ki67 was confirmed as high if >20% cells stained (using a median cut-off from a larger cohort). Immunostaining data were unavailable for a limited number of cases.
RT-PCR analysis
Total RNA was provided by the CTBRC. Following a DNAaseI digestion step (Invitrogen), reverse transcription (RT) was performed in duplicate on 0·5 µg RNA according to the manufacturer's instructions. RT reactions incorporated Superscript II Reverse Transcriptase (Invitrogen), 0·5 µg Oligo (dT) 17 and 0·5 µl Prime Recombinant Ribonuclease Inhibitor (Eppendorf, Cambridge, UK). Parallel reactions were performed in which the RT enzyme was omitted and these acted as controls for genomic DNA contamination. PCR reactions (20 µl) were performed in duplicate in 96-well plates, each using 2 µl of a 1/20 dilution of cDNA (equivalent to cDNA from approximately 2·5 ng total RNA). PCR reactions included 0·2 mM dNTPs, 0·5 U HotstarTaq DNA polymerase (Qiagen) and 1×PCR Buffer (containing 1·5 mM MgCl 2 ; Qiagen). Primer and MgCl 2 concentrations varied as per Table 2 . The oligonucleotide primers (Table 2) for ER 1 and ER 2/5 RT-PCR were taken from Moore et al. (1998) .
-Actin and hypoxanthine ribosyltransferase (HPRT) were used as control genes for determination of RNA integrity and RT efficiency and positive controls (testis and MCF7 cells) were included. Each PCR reaction was limited in cycle number and/or primer concentration, so as to avoid the plateau phase of the reaction, but otherwise cycle number was maximised to give maximum sensitivity for each gene product. PCR was performed on Perkin Elmer 9600 thermal cyclers and all reactions (Table 2) included a 94 C 13 min activation and a 72 C 3 min final extension. PCR products were separated by electrophoresis on gels containing 2·5% Seakem Agarose (Flowgen, Ashby de la Zouch, Leics, UK) and 40 mM Trisacetate, 1 mM EDTA, pH 7·6 buffer. Molecular mass markers (PhiX174/HaeIII; Abgene, Epson, Surrey, UK) were included on each gel and DNA was visualised by inclusion of 0·5 µg/ml ethidium bromide, scanning with a Molecular Dynamics FluorimagerSI and analysis with ImageQuant v. 4·1 (Amersham Biosciences). Control genes were scored as weak or strong positive and individual RT reactions excluded from ER assessment if either was negative, or if both were weak. Cases were considered positive for ER RT-PCR if any band was scored as positive by two independent investigators. Identity of PCR products was confirmed by direct sequencing using DYEnamicET Dye Terminator Cycle Sequencing Kit for MegaBACE (Amersham Biosciences) and analysed on a MegaBACE1000 (Amersham Biosciences). Alternatively PCR products were cloned using TOPO-TA cloning (Invitrogen) prior to sequence analysis.
Statistical analysis
All statistical analyses were performed using the SPSS package (Windows, v. 11). To compare immunostaining percentage values in different groups, data were analysed by the non-parametric, two-sided Mann-Whitney test. Association between categorical data was assessed by the Chi-squared test, with contingency coefficients (Cont. Coeff.) calculated to assess the strength of different associations. Survival curves were generated using the Kaplan-Meier method for censored data and compared using the log-rank test. Cox's regression models were used to determine hazard ratios and for multivariate survival analysis.
Results
RT-PCR
The identities of representative RT-PCR products for each gene were confirmed by sequence analysis. No evidence of artefactual PCR products due to genomic DNA contamination was seen. The use of control genes -actin and HPRT identified 105 cases in which cDNA was considered of appropriate quantity and integrity for further analysis. RT-PCR analysis of these 105 cases categorised 70% of cases ER 1 positive, 69% ER 2 positive and 70% ER 5 positive (Table 1) and these percentages were similar in the cohort of 56 ER -positive, adjuvant tamoxifen-only cases. A wide variety of expression 
Relationship of ER RT-PCR with clinical and immunohistological parameters
The relationships between each of the ER RT-PCR scores (ER 1, ER 2, ER 5) and the clinical and immunohistological parameters, presented in Table 1 were examined by the Chi-squared test. RT-PCR data for ER showed no association with any treatment groups, histology or tumour size. There was no association of any ER RT-PCR with ER , PgR or Ki67 staining and this was confirmed using a Mann-Whitney test for differences in staining strength (per cent positive cells) between RT-PCR-positive and -negative groups.
Some association was seen between ER 2 and tumour grade; ER 2 was positive in 89% of grade I, 52% of grade II and 76% of grade III tumours and RT-PCR-positive scores were significantly associated with grade I (Chi-squared, P=0·007) or grade III (Chi-squared, P=0·024) tumours as opposed to grade II tumours.
Relationship of ER RT-PCR with disease outcome
To examine the possible effect of ER status in relation to endocrine treatment, outcome data have been restricted to those 105 women receiving endocrine treatment either with or without neoadjuvant tamoxifen treatment, but with no primary or adjuvant chemotherapy (Table 1 ). The median time to relapse for this cohort was 75·7 months (inter-quartile range 61·2-90·3) and the median time to death was 93·8 months (inter-quartile range 68·4-119·2). Subgroup analysis within this cohort was also carried out on the 65 ER -positive cases and the 56 ER -positive cases receiving adjuvant tamoxifen only (Table 3) .
In the 105 case cohort, high grade, positivenodal status, larger size, ER -negative status, PgR-negative status and high Ki67 status were all associated with worse prognosis (Table 1 ). In addition, histopathological features other than invasive ductal carcinoma, were associated with a moderately better overall survival (OS) ( Table 1) . The choice of surgery, radiotherapy or endocrine treatment was of no significance for patient outcome. ER 2 was associated with significantly better relapse-free survival (RFS) (Fig. 2) and OS ( Table 1) , while ER 5 was also associated with better RFS. ER 1 was not significantly associated with any measure of survival. For ER 2-negative patients, the median time to relapse was 38·1 months (inter-quartile range 6·6-69·5) and the median time to death was 51·2 months (interquartile range 32·6-69·8). In contrast, median time to either measure of outcome was not reached for ER 2-positive cases. In multivariate analysis, nodal status (P=0·003), Ki67 (P=0·0004) and ER 2 (P=0·006) were independent markers of RFS and only Ki67 (P=0·003) and ER 2 (P=0·0008) were independent markers of OS.
With respect to the ER -positive cases, irrespective of treatment (n=65), the only significant markers for RFS are nodal status (log-rank P=0·011), Ki67 (P=0·039), ER 2 (P<0·0001) and ER 5 (P=0·002). Of these, only nodal status (P=0·011) and Ki67 (P=0·028) are independently significant for RFS in multivariate analysis. For OS, grade (P=0·033), ER 2 (P=0·0001) and ER 5 (P=0·042) are significant by log-rank, but only ER 2 is independent in multivariate analysis (P=0·0002). The same markers were significant even in the smallest sub-group analysed (the 56 ER -positive, tamoxifen-only cases). As shown in Table 3 , ER variants, grade, nodal status and Ki67 were all significantly related to RFS or OS, with ER 2 being the best predictor of OS.
Discussion
The study reported herein strongly supports the initial hypothesis that different ER splice variants are important determinants, and hence predictors of clinical parameters including outcome, in post-menopausal women with breast cancer treated only by adjuvant hormonal manipulation. The study also confirms that individual primary breast cancers are heterogeneous with respect to the spectrum of ER splice variants expressed. Thus, a single breast cancer might simultaneously express different isoforms of the receptor that are potentially agonist, antagonist or unresponsive with respect to interaction with a potential inhibitor (e.g. tamoxifen). Of the three splice variants examined, expression of ER 2 was clearly beneficial with respect to RFS (Fig. 2B) . The advantage conferred by ER 5 was less pronounced (Fig. 2C) . These two variants are likely to contribute to the association of ER with better outcome in RT-PCR studies using primers that amplify total ER . Conversely, expression of ER 1 mRNA apparently confers no statistically significant advantage, with respect to RFS or OS. In common with most previous observations, the current data reveal few associations between ER mRNAs and either clinical or histological features. This observation alone emphasises the complexity of the multiplicity of factors contributing to clinical behaviour and to histopathological appearances. Both grade I and III groups did have significantly higher proportions of RT-PCR-positive cases for ER 2 when compared with grade II cases. Although not reported in other RT-PCR studies, an association of ER protein and high grade was identified by Myoshi et al. (2001) using an antibody that is likely to be pan-variant. Others using similarly non-specific antisera (Skliris et al. 2001) have reported associations with low-grade tumours.
Unlike ER , which is bimodally distributed with respect to expression in breast cancers, others have reported a diverse range of ER mRNA levels using quantitative RT-PCR (Bieche et al. 2001) making assignment of meaningful cut-off values difficult. Use of semi-quantitative RT-PCR in the manner described here imposes an arbitrary cut-off dependent on the sensitivity of the RT-PCR reaction and the detection technique. The assignment of a meaningful and valid cut-off is complex and would rely on more quantitative approaches. Despite this caveat, the use of our cut-off has distinguished statistically significant groups of cases based upon ER 2 or ER 5 status. Use of a higher cut-off, e.g. by reassigning the ten weakest ER 2 RT-PCR-positive cases as negative leads to a diminished log-rank score, but a significant relationship with outcome is maintained (P<0·005). It is possible that the lack of significant association between ER 1 and disease outcome is due, at least in part, to the technical limitations of this approach. However, the relative number of cases positive for ER 1, ER 2 and ER 5 RT-PCR product is similar, suggesting that the distribution of ER 1 is distinct. Despite almost half of the cases expressing all three variants, expression of ER 1 was found to be more diverse while ER 2 and ER 5 were more closely related.
In previous studies the relationship between ER and disease outcome in breast cancer patients has not been comprehensively evaluated, primarily since most early studies concentrated on the role of ER in the wider context of breast cancer pathology. Two studies that included outcome data reported no relationship with ER RT-PCR (Kurebayashi et al. 2000 , Bieche et al. 2001 . Both studies employed non-specific RT-PCR, which has now been demonstrated to be an inferior marker to variant-specific RT-PCR. Furthermore, case selection was different such that premenopausal patients were included with no account being taken of treatment. Speirs et al. (1999a) reported increased ER mRNA expression in tamoxifen-resistant breast cancer patients. Again non-specific RT-PCR was used, follow-up was limited to time receiving tamoxifen and the association was based on a small number of cases (n=17).
While demonstration that particular ER splice variant mRNAs are related to disease outcome is potentially important as a molecular marker, more direct involvement in the disease process would rely on protein expression. Some relationship between ER expression and outcome has been reported using immunohistochemistry (Mann et al. 2001 , Omoto et al. 2001 , Saji et al. 2002 . Nevertheless, it is difficult to compare the current RT-PCR data with immunohistological appearances; although splice variants are expressed as protein, the quantitative relationship between mRNA and protein for ER is not clear. Omoto et al. (2001 Omoto et al. ( , 2002 found a weak association between ER 1 protein and better outcome, but no significant results for other variants, albeit with smaller numbers of cases from non-selective cohorts. Saji et al. (2002) found that a greater proportion of ER 2-negative cases responded to primary tamoxifen treatment, implying an association of ER 2 with worse response. This observation is in contrast to our current findings, but the number of cases studied was very small (18 ER -positive core biopsies), and it is unclear how response in this neoadjuvant setting relates to adjuvant treatment and longer-term outcome. Mann et al. (2001) studied the immunohistochemical expression of ER in patients treated with adjuvant tamoxifen and showed ER -positive patients to have a better survival when compared with ERnegative patients. Although the contribution of individual ER variants is unclear since the employed antibody was of broad specificity, if ER 2 expression contributes to the ER expression measured, these findings support the current data. Recently further supportive information has emerged from a study of ER 2 using variant-specific Western blot analysis (Palmieri et al. 2004a) . Here the presence of ER 2 was associated significantly with longer survival and with a better endocrine-treatment response. Our results indicate a stronger association between ER 2 and outcome and reasons for this include differences in the patient groups studied and the method of detection for ER 2 expression. Palmieri et al. (2004b) do not report the treatment received by the majority of patients in their study, cases included locally advanced and metastatic disease and endocrine-treatment response was evaluated in only 23 patients receiving neoadjuvant or palliative therapy. That significant associations between ER 2 and outcome or response were found is testament to the potential importance of this marker, as the authors failed to find any association between outcome and ER status (Palmieri et al. 2004a) . Hence our results more directly address the importance of ER 2 in the important clinical setting of adjuvant endocrine treatment, while those of Palmieri et al. suggest that ER 2 protein expression as well as ER 2 mRNA is related to a better outcome.
Both our findings and those of Palmieri et al. (2004a) make use of heterogeneous breast samples and it is possible that non-tumour cells contribute to the expression seen. This is potentially of some importance as it seems that, unlike ER , ER and some of its splice variants can be expressed in stromal cells of human breast (Palmieri et al. 2004b ). However, using Western blots and immunostaining on the same tumour samples (Palmieri et al. 2004a) these techniques result in >80% agreement and immunostaining is predominantly epithelial. Such results would suggest that in most cases results from heterogeneous samples reflect tumour cell expression of ER 2, but that in situ techniques should be applied to address this issue in more detail.
Since it has been proposed that ER 2 can act as a dominant negative regulator of ER (Ogawa et al. 1998) , the association of ER 2 expression with better disease outcome is not unexpected. We suggest that, in breast cancer, inhibition of ER function associated with high levels of ER 2 acts alongside tamoxifen to promote a better outcome. In summary, this study has provided new evidence to support the hypothesis that ER splice variant expression is an important determinant of breast cancer phenotype, including response to hormonal manipulation in post-menopausal women with ER -positive tumours. Further studies are now required to relate expression of individual ER isoforms to particular patterns of tumour behaviour, including response to different ER antagonists.
